Both autologous and allogeneic haemopoietic stem cell transplantation (HSCT) have been tried in Crohn's disease (CD). In allogeneic HSCT, the host bone marrow is ablated and replaced by bone marrow from a donor. This substitution of a genetically different bone marrow is effective in a number of conditions including those with an immunological basis such as CD. While the toxicity of allogeneic HSCT has precluded its uptake in idiopathic CD, there is interest in its utility in the management of early onset infantile (inflammatory bowel disease), which behaves as a monogenic disorder, with abnormalities of the interleukin 10 signalling system as the best recognized. In autologous HSCT, the patient's own stem cells are harvested before proceeding to lymphoablation and transplantation of the patient's own uncommitted stem cells, which generate an immune system with an altered T-cell repertoire. In a limited number of cases, this has led to substantial and prolonged remission tantamount to possible cure of CD. However, case series and controlled data from the Autologous Stem Cell International Crohn's Disease study suggest that although this method has its own advantages, most patients are still at risk of redeveloping CD, albeit with an arguably improved response to conventional treatment. The availability of new treatments for CD means that an HSCT is not a suitable treatment method for a majority of patients because of its greater toxicity, even though efficacy may be superior. Wider usage would depend upon the development of protocols that are safer and better targeted.

Keywords:
Haemopoietic stem cells, Transplantation, Crohn’s disease, Inflammatory bowel disease, Infantile
1.
Li HW, Sykes M: Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol 2012;12:403-416.
2.
Majhail NS, et al: Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:1863-1869.
3.
Snowden JA, Saccardi R, Allez M, et al: Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47:770-790.
4.
Glocker EO, et al: Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-2045.
5.
Engelhardt KR, et al: Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013;131:825-830.
6.
Murugan D, et al: Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. J Clin Immunol 2014;34:331-339.
7.
Uhlig HH, Schwerd T: From genes to mechanisms: the expanding spectrum of monogenic disorders associated with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:202-212.
8.
Lopez-Cubero SO, et al: Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998;114:433-440.
9.
Farge D, et al: Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010;95:284-292.
10.
Alexander T, et al: Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009;113:214-223.
11.
Burt RK, et al: Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.
12.
van Laar JM, et al: Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490-2498.
13.
Muraro PA: Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS. Neurology 2015;84:968-969.
14.
Hawkey CJ, et al: Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 2015;314:2524-2534.
15.
Muraro PA, et al: T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 2014;124:1168-1172.
16.
Abrahamsson SV, et al: Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 2013;136(pt 9):2888-2903.
17.
Darlington PJ, et al: Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013;73:341-354.
18.
Clerici M, et al: Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis 2011;43:946-952.
19.
Hawkey CJ: Stem cell transplantation for Crohn's disease. Best Pract Res Clin Haematol 2004;17:317-325.
20.
Kashyap A, Forman SJ: Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. Br J Haematol 1998;103:651-652.
21.
Kreisel W, et al: Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant 2003;32:337-340.
22.
Oyama Y, Craig RM, Traynor AE, et al: Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005;128:552-563.
23.
Burt RK, Craig RM, Milanetti F, et al: Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010;116:6123-6132.
24.
Cassinotti A, et al: Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008;57:211-217.
25.
Hasselblatt P, et al: Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther 2012;36:725-735.
26.
Hommes DW, et al: Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. J Crohns Colitis 2011;5:543-549.
27.
Jauregui-Amezaga A, et al: Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease Gut 2016;65:1456-1462.
28.
Best WR, Becktel JM, Singleton JW: Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77(4 pt 2):843-846.
29.
Harvey RF, Bradshaw JM: A simple index of Crohn's-disease activity. Lancet 1980;1:514.
30.
Daperno M, D'Haens G, Van Assche G, et al: Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-512.
31.
Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH: The use of nitrogen mustards in the palliative treatment carcinoma. Cancer 1948;1:634-656.
32.
Irvine EJ, Feagan B, Rochon J, et al: Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-296.
33.
Dolan P, Roberts J: Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Med Care 2002;40:442-446.
34.
Hanauer SB, Feagan BG, Lichtenstein GR, et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.
35.
Colombel JF, Sandborn WJ, Rutgeerts P, et al: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
36.
Sandborn WJ, Gasink C, Gao LL, et al: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-1528.
37.
Sandborn WJ, Feagan BG, Rutgeerts P, et al: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
38.
Lees CW, et al: New IBD genetics: common pathways with other diseases. Gut 2011;60:1739-1753.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.